[밸류업 점검] 메디톡스, 고배당 유지 전면…법무비·수출 과제

Medytox is prioritizing shareholder returns through a robust dividend policy, yet its success hinges on balancing high payouts with rising legal costs and the production ramp-up of NEWLUX. The market is closely watching whether the company's aggressive global export expansion can offset its current profitability squeeze to ensure the long-term sustainability of its Value-up initiative.